Separately, ValuEngine downgraded Atrion from a “buy” rating to a “hold” rating in a research report on Friday, July 26th.
Shares of NASDAQ ATRI traded down $1.36 during midday trading on Thursday, reaching $779.63. 21,984 shares of the stock traded hands, compared to its average volume of 29,122. The stock has a market capitalization of $1.42 billion, a PE ratio of 39.62 and a beta of 0.20. Atrion has a one year low of $665.25 and a one year high of $948.03. The company’s 50 day moving average is $777.67 and its 200 day moving average is $827.48.
Atrion (NASDAQ:ATRI) last issued its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $5.18 earnings per share (EPS) for the quarter. The company had revenue of $40.10 million during the quarter. Atrion had a return on equity of 16.79% and a net margin of 23.14%.
Large investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its stake in Atrion by 0.6% in the second quarter. AQR Capital Management LLC now owns 2,677 shares of the medical instruments supplier’s stock valued at $2,283,000 after purchasing an additional 17 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in Atrion by 10.3% in the second quarter. Envestnet Asset Management Inc. now owns 322 shares of the medical instruments supplier’s stock worth $275,000 after acquiring an additional 30 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in Atrion by 1.4% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 4,183 shares of the medical instruments supplier’s stock worth $3,676,000 after acquiring an additional 58 shares in the last quarter. Pennsylvania Trust Co boosted its holdings in Atrion by 0.6% in the third quarter. Pennsylvania Trust Co now owns 10,329 shares of the medical instruments supplier’s stock worth $8,048,000 after acquiring an additional 65 shares in the last quarter. Finally, Krane Funds Advisors LLC acquired a new stake in Atrion in the second quarter worth about $57,000. Institutional investors and hedge funds own 64.69% of the company’s stock.
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Featured Article: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.